Evogene's CEO to present at H.C. Wainwright Global Investment Conference 2025.
ByAinvest
Thursday, Aug 28, 2025 7:06 am ET1min read
EVGN--
The presentation will highlight Evogene's new strategic focus on leveraging ChemPass AI to address key challenges in small molecule discovery and optimization. By utilizing its tech-engine, Evogene aims to increase the probability of success while reducing time and development costs. The company's powerful tech-engine drives product innovation through strategic partnerships and collaborations, as well as through its internal proprietary product pipelines [2].
Haviv will be available for one-on-one meetings with interested investors and companies attending the conference. The event provides an opportunity for attendees to gain insights into Evogene's innovative approach to small molecule discovery and optimization, and to discuss potential collaboration opportunities [1][2].
References:
[1] https://www.stocktitan.net/news/EVGN/evogene-to-present-at-h-c-wainwright-27th-annual-global-investment-rv446tvcm7no.html
[2] https://www.prnewswire.com/news-releases/evogene-to-present-at-hc-wainwright-27th-annual-global-investment-conference-in-new-york-302540962.html
Evogene Ltd. announced that CEO Ofer Haviv will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025. Haviv will highlight the company's new strategic focus on maximizing the value of ChemPass AI, a generative AI tech-engine for small molecule discovery and optimization in pharmaceuticals and agriculture. The presentation is scheduled for September 10, 2025, at 1:00 PM ET, and Haviv will be available for one-on-one meetings.
Evogene Ltd. (NASDAQ: EVGN) has announced that CEO Ofer Haviv will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. Haviv's presentation, scheduled for September 10, 2025, at 1:00 PM ET, will focus on the company's strategic shift towards maximizing the value of ChemPass AI, a proprietary generative AI tech-engine for small molecule discovery and optimization in pharmaceuticals and agriculture [1][2].The presentation will highlight Evogene's new strategic focus on leveraging ChemPass AI to address key challenges in small molecule discovery and optimization. By utilizing its tech-engine, Evogene aims to increase the probability of success while reducing time and development costs. The company's powerful tech-engine drives product innovation through strategic partnerships and collaborations, as well as through its internal proprietary product pipelines [2].
Haviv will be available for one-on-one meetings with interested investors and companies attending the conference. The event provides an opportunity for attendees to gain insights into Evogene's innovative approach to small molecule discovery and optimization, and to discuss potential collaboration opportunities [1][2].
References:
[1] https://www.stocktitan.net/news/EVGN/evogene-to-present-at-h-c-wainwright-27th-annual-global-investment-rv446tvcm7no.html
[2] https://www.prnewswire.com/news-releases/evogene-to-present-at-hc-wainwright-27th-annual-global-investment-conference-in-new-york-302540962.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet